Pharvaris NV logo

Pharvaris NVNASDAQ: PHVS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Netherlands

IPO:

05 February 2021

Next earnings report:

10 April 2025

Last dividends:

N/A

Next dividends:

N/A
$1.11 B
-32%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector
-62%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Tue, 19 Nov 2024 21:00:00 GMT
$20.51-$0.41(-1.96%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PHVS Latest News

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
globenewswire.com13 November 2024 Sentiment: POSITIVE

ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced financial results for the third quarter ended September 30, 2024, and highlighted recent business updates.

Pharvaris to Host Virtual Investor Event on October 23, 2024
globenewswire.com15 October 2024 Sentiment: POSITIVE

ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced it will host a virtual investor event to discuss the unmet need in both the prophylactic and on-demand treatment of HAE attacks, the potential of deucrictibant to address to needs, and the current HAE market dynamics, on Wednesday, October 23, 2024, at 10:00 a.m. ET/16:00 CET. To register, click here.

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com14 August 2024 Sentiment: POSITIVE

ZUG, Switzerland, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the financial results for the second quarter ended June 30, 2024, and provided a business update.

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
globenewswire.com04 June 2024 Sentiment: POSITIVE

ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, recently presented data highlighting the unique pharmacological and clinical properties of deucrictibant for the treatment and prevention of HAE attacks at the 20 th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024.

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
GlobeNewsWire04 April 2024 Sentiment: POSITIVE

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
GlobeNewsWire06 March 2024 Sentiment: POSITIVE

ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA), to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas, to be held from March 15-17, 2024, in Panama City, Panama. Details of the presentations are as follows:

Pharvaris to Present at the WSAAI Annual Meeting 2024
GlobeNewsWire26 January 2024 Sentiment: POSITIVE

ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024, to be held from February 4-8, 2024, at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii.

Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
Zacks Investment Research07 December 2023 Sentiment: POSITIVE

Data from a mid-stage study shows that treatment with Pharvaris' (PHVS) investigational HAE drug reduced the monthly attack rate by 84.5%.

Why Is Pharvaris (PHVS) Stock Up 36% Today?
InvestorPlace06 December 2023 Sentiment: POSITIVE

Pharvaris (NASDAQ: PHVS ) stock is rising higher on Wednesday after the clinical-stage biopharmaceutical company announced an underwritten offering for its shares. That offering includes 11,125,000 shares of PHVS stock sold to one investor for a price of $24 each.

Pharvaris shares surge as treatment for severe swelling meets clinical trial goal
Market Watch06 December 2023 Sentiment: POSITIVE

Shares of Pharvaris N.V. PHVS, +14.98% jumped 40% premarket on Wednesday after the Switzerland-based company said an investigational drug met its primary goal in a clinical trial for treatment and prevention of hereditary angioedema attacks.

What type of business is Pharvaris NV?

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

What sector is Pharvaris NV in?

Pharvaris NV is in the Healthcare sector

What industry is Pharvaris NV in?

Pharvaris NV is in the Biotechnology industry

What country is Pharvaris NV from?

Pharvaris NV is headquartered in Netherlands

When did Pharvaris NV go public?

Pharvaris NV initial public offering (IPO) was on 05 February 2021

What is Pharvaris NV website?

https://pharvaris.com

Is Pharvaris NV in the S&P 500?

No, Pharvaris NV is not included in the S&P 500 index

Is Pharvaris NV in the NASDAQ 100?

No, Pharvaris NV is not included in the NASDAQ 100 index

Is Pharvaris NV in the Dow Jones?

No, Pharvaris NV is not included in the Dow Jones index

When was Pharvaris NV the previous earnings report?

No data

When does Pharvaris NV earnings report?

The next expected earnings date for Pharvaris NV is 10 April 2025